FDA announces first drug shortage in US caused by impact of COVID-19
The FDA has released a statement, announcing that the US is experiencing its first shortage as a result of the effects of COVID-19.
List view / Grid view
News
EMA releases results from February meeting, recommending two medicines
The EMA has recommended granting marketing authorisation to two medicines and extending the indications for three more following its latest meeting.
Technique to synthesise aziridines developed by researchers
Eliminating expensive catalysts, researchers have shown it is possible to transfer nitrogen atoms to unactivated olefins for the production of aziridines.
MHRA issues alerts over defects in Patient Information Leaflets
The MHRA has issued two alerts, one for incorrect maximum daily dosage of Ibuprofen 400mg and a second for missing safety information about Oxylan Prolonged-release tablets.
FDA approves Advil Dual Action for over-the-counter pain relief
Advil Dual Action is the first FDA-approved an over-the-counter ibuprofen and acetaminophen combination, backed up with data from several clinical trials proving its efficacy.
Lenalidomide recommended for use with rituximab by NICE
NICE has given its positive opinion to lenalidomide in combination with rituximab as a 'chemotherapy-free' treatment for lymphoma.
American Health Packaging voluntarily recalls ranitidine tablets
Ranitidine tablets have been recalled due to the possibility of the products containing unacceptable levels of NDMA.
Global collaboration formed to develop novel treatment regimens for TB
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) was devised to create transformative regimens for TB treatment, irrespective of drug resistance status.
Collaboration for 3D printing of tablets announced
Two companies have announced their partnership to work on the 3D printing of tablets for use in clinical trials.
Europe’s no 1 trade fair for the fine and speciality chemicals industry returns to Cologne with a strong line-up
Chemspec Europe, the International Exhibition for Fine and Speciality Chemicals, returns to Cologne for its 35th edition. From 27 – 28 May 2020, renowned manufacturers, suppliers and distributors of fine and speciality chemicals present their latest products, services and research findings to a dedicated audience of industry experts.
Takeda acquires PvP Biologics following coeliac disease drug trial
A statement by the Takeda reveals the company has acquired PvP as part of a development and option agreement for the drug TAK-062.
NICE does not recommend polatuzumab vedotin to treat lymphoma
NICE has formed a negative opinion for Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine to treat diffuse large B-cell lymphoma.
Biocatalysis could be the key to shaping macrocycles
Researchers have shown that the CALB lipase enzyme can be used to produce macrocycles of a specified shape using biocatalysis.
FDA and EMA accept licence applications for multiple sclerosis treatment
The FDA and EMA have accepted licence applications for ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS).
Coronavirus update: clinical trials and antibody manufacture
The US NIH has initiated a clinical trial for remdesivir and two pharmaceutical companies will work together to manufacture antibody treatments to tackle the coronavirus.
